A Single-arm, Phase II Study of Camrelizumab Combined With S-1 Maintenance After First-Line Induction Chemotherapy in Patients With HER2 Negative Advanced Gastric Cancer
Latest Information Update: 03 Jan 2022
At a glance
- Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
- Focus Therapeutic Use
Most Recent Events
- 03 Jan 2022 New trial record